The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Neurocrine Biosciences, Inc shares valued at $1,155,290 were purchased by KEVIN CHARLES GORMAN on May 27 ’25. At $120.18 per share, KEVIN CHARLES GORMAN acquired 9,613 shares.
Also, RASTETTER WILLIAM H sold 30,000 shares, netting a total of over 3,305,952 in proceeds. Following the sale of shares at $110.20 each, the insider now holds 37,491 shares.
Before that, WILLIAM H. RASTETTER had added 30,000 shares to its account. In a trade valued at $3,290,400, the Officer bought Neurocrine Biosciences, Inc shares for $109.68 each.
As published in a research note from Needham on April 15, 2025, Neurocrine Biosciences, Inc [NBIX] has been rated up from a Hold to a Buy and the price target has been revised to $138. Analysts at RBC Capital Mkts upgraded the stock from ‘”a Sector perform”‘ to ‘”an Outperform”‘ outlook in a report released in mid April. As of February 11, 2025, Deutsche Bank has initiated its “Hold” rating for NBIX.
Analyzing NBIX Stock Performance
During the last five days, there has been a surge of approximately 0.06%. Over the course of the year, Neurocrine Biosciences, Inc shares have dropped approximately -9.87%. Shares of the company reached a 52-week high of $154.61 on 01/30/25 and a 52-week low of $84.23 on 04/09/25.
Support And Resistance Levels for Neurocrine Biosciences, Inc (NBIX)
According to the 24-hour chart, there is a support level at 122.23, which, if violated, would cause prices to drop to 121.44. In the upper region, resistance lies at 124.06. The next price resistance is at 125.10. RSI (Relative Strength Index) is 63.62 on the 14-day chart, showing neutral technical sentiment.
